Modelling cure from cancer accounting for inevitable mortality
Journal of the Royal Statistical Society Series C: Applied Statistics · 21.07.2026
DOI: 10.1093/jrsssc/qlag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Royal Statistical Society Series C: Applied Statistics, online erschienen am 21.07.2026. Verfasst von Suvra Pal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, University of Texas at Arlington, Arlington, TX 76019, United States. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute Of General Medical Sciences of the National Institutes of Health, National Institutes of Health.
Abstract (Originalsprache)
Cancer remains the second most prevalent cause of death in the USA, claiming 605,213 lives in 2021, surpassing COVID-19 deaths. The cancer mortality rate continued to decline between 2019 and 2020, dropping by 1.5%, marking a significant 33% decrease since 1991. This ongoing improvement primarily mirrors advances in treatment, allowing patients to achieve clinical remission and recovery. Now, a cancer patient is simultaneously exposed to the risk of primary cancer as well as other risks, such as other cancer(s) or other diseases, leading to a competing risks scenario. Analysis of survival data under competing risks and the presence of cured patients have been extensively studied individually, but there is limited work in the current literature that models the possibility of cure from one risk in the presence of competing risks. Moreover, such a model should allow for the possibility of cure from the cause-specific risk of the primary cancer; however, the overall survival probability should eventually approach zero, thereby incorporating the prevalent belief of eventual failure with certainty. We propose a novel unified competing risks cure model, based on the cause-specific hazard approach, that satisfies the aforementioned desired properties. The conditions required to establish model identifiability are studied in detail. To find the maximum likelihood estimates of the model parameters, a computationally efficient expectation maximization algorithm is developed. An extensive simulation study is carried out to demonstrate the performance of the proposed model and estimation method under different parameter settings and in the presence of multiple competing risks. Finally, an application is illustrated using breast cancer data from the Surveillance, Epidemiology, and End Results cancer database.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Mathematics, University of Texas at Arlington, Arlington, TX 76019, United States.
- Division of Data Science, College of Science, University of Texas at Arlington, Arlington, TX 76019, United States.
- Merck & Co., Inc., Rahway, NJ, USA.
- AbbVie Inc., North Chicago, Illinois, USA.
- Division of Epidemiology and Biostatistics, University of Illinois Chicago.
- Department of Statistics, University of Florida.
Förderung
- NIGMS NIH HHS
- National Institute Of General Medical Sciences of the National Institutes of Health
- National Institutes of Health
- Research Enhancement Programme
- University of Texas at Arlington
- National Science Foundation
Zitieren
APA
Pal, S., Rathmann, S. S., Jiang, Q., Sun, J., Sinha, D., & Basu, S. (2026). Modelling cure from cancer accounting for inevitable mortality. Journal of the Royal Statistical Society Series C: Applied Statistics. https://doi.org/10.1093/jrsssc/qlag040
Vancouver
Pal S, Rathmann SS, Jiang Q, Sun J, Sinha D, Basu S. Modelling cure from cancer accounting for inevitable mortality. Journal of the Royal Statistical Society Series C: Applied Statistics. 2026. doi:10.1093/jrsssc/qlag040
BibTeX
@article{Pal2026,
author = {Pal, Suvra and Rathmann, Suchitrita Sarkar and Jiang, Qi and Sun, Jiehuan and Sinha, Debajyoti and Basu, Sanjib},
title = {Modelling cure from cancer accounting for inevitable mortality},
journal = {Journal of the Royal Statistical Society Series C: Applied Statistics},
year = {2026},
doi = {10.1093/jrsssc/qlag040}
}
EUVIMED